New Migraine Burden Index Proves Accurate, Strongly Correlates With Patient Satisfaction
June 9th 2021Investigators conducted a 9-month study that demonstrated the correlation of the MBI, calculated as the sum of headache days times the maximum intensity of headache on each headache day, with satisfaction of migraine status.
Despite Slight Differences, Preventive Migraine Therapies Demonstrate High Efficacy
June 9th 2021Researchers used a connected network of studies that were generally well balanced in terms of key baseline characteristics, such as baseline MMD and use of prior therapies, to compare preventive treatments.
NeuroVoices: Andrew Blumenfeld, MD, on a Combination Approach to Treating Chronic Migraine
June 9th 2021The director for the Headache Center of Southern California discussed his research presented at AHS 2021 which evaluated a combination of onabotunlinumtoxinA and CGRPs in patients with chronic migraine.
Aducanumab for Alzheimer Disease: Landmark Moment or False Hope for Patients?
June 8th 2021Experts in the treatment and management of patients with Alzheimer disease and dementia, including Marwan Sabbagh, MD; Lon Schneider, MD, MS; Anton Porsteinsson, MD; and Robert Howard, MD, MRCPsych, weigh in on the FDA's controversial approval of Biogen's anti-amyloid drug, aducanumab.
Survey Suggests Need for Migraine Treatment Standardization Among Women’s Healthcare Providers
June 5th 2021Respondents reported varying levels of comfort regarding the management of migraine during pregnancy, with only half of women’s healthcare providers indicating they conducted counseling on migraine during pregnancy.